| TOP STORY | MicroRNA-7 Regulates the mTOR Pathway and Proliferation in Adult Pancreatic β-Cells Researchers showed that the microRNA (miR)-7/7ab family member miR-7a is enriched in mouse adult pancreatic islets compared with miR-7b. Remarkably, miR-7a targets five components of the mTOR signaling pathway. Furthermore, inhibition of miR-7a activates mTOR signaling and promotes adult β-cell replication in mouse primary islets, which can be reversed by the treatment with mTOR inhibitor, rapamycin. [Diabetes] Abstract |
| INDUSTRY NEWS | Poxel Raises €13 Million to Progress Imeglimin Development to Treat Type 2 Diabetes Poxel SA announced that it has raised €13 million in a Series B round. The financing was led by Edmond de Rothschild Investment Partners and included all existing investors: InnoBio fund managed by CDC Entreprises within FSI France Investment program; and Omnes Capital. A significant part of the funds will be used to confirm efficacy data of the company’s lead program, Imeglimin, a novel anti-diabetic agent. [Poxel SA] Press Release Swift Transportation Donates More than $15,000 to The Waylon Fund Swift Charities, the charitable arm of Swift Transportation, donated $15,262 to The Waylon Jennings Fund for Diabetes Research at the Translational Genomics Research Institute. [The Translational Genomics Research Institute] Press Release New Facility Will Bridge Research and Stem Cell Therapies The University of Rochester Medical Center has opened the doors on a new facility that will enable researchers to create, study, and ultimately use stem cells and their offspring in early-phase experimental human therapies. The Upstate Stem Cell cGMP Facility was created with $3.5 million in support from the Empire State Stem Cell Board. [University of Rochester Medical Center] Press Release |
|
|
|